Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol
March 02 2022 - 8:30AM
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage
pharmaceutical company focused on modulating lipid-signaling
pathways to develop treatments for people living with cancer, pain,
and neurological conditions, announced that the Company received a
Notice of Allowance from the U.S. Patent and Trademark Office
(USPTO) for patent application 16/835,383 entitled “Solid Forms of
Cannabidiol and Uses Thereof” related to its ART12.11 program, a
cocrystal composition of cannabidiol (CBD). In addition, the
Company has pending foreign patent applications covering cocrystal
composition-of-matter and method of use.
“The method of use claims of this patent
combined with the CBD cocrystal’s composition of matter patent
already issued in the US further enhances our overall intellectual
property portfolio,” stated Gregory D. Gorgas, President and CEO of
Artelo Biosciences. “Our strategy is to leverage the strength of
our science and patents to develop important advancements in the
treatment of serious conditions, such as PTSD and cancer, as we
target large and underserved markets where we believe our patent
portfolio provides a distinct competitive advantage.”
This patent claims methods for treating a
disease or condition selected from central nervous system
disorders, cardiovascular disorders, neurovascular disorders,
neuromuscular disorders, cancers, autoimmune disorders,
inflammation, pain, sleep disorders, posttraumatic stress disorder,
posttraumatic stress syndrome; nausea, and hypoxia-ischemia. It is
expected this patent will have a patent term until 2038, not
including any possible patent term extensions.
About ART12.11ART12.11 is a
proprietary cocrystal composition of cannabidiol (CBD). The crystal
structure of CBD is known to exhibit solid polymorphism, or the
ability to manifest in different forms. Artelo believes its
cocrystal exists as a single crystal form and, as such, is
anticipated to have advantages over other solid forms of CBD that
exhibit polymorphism. Anticipated advantages of this single crystal
structure include improved stability, solubility, and a more
consistent absorption profile. Artelo believes these features will
result in more consistent and improved bioavailability and may
ultimately lead to improved safety and efficacy.
About Artelo BiosciencesArtelo
Biosciences, Inc. is a clinical-stage pharmaceutical company
dedicated to the development and commercialization of proprietary
therapeutics that target lipid-signaling pathways, including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical
executives collaborating with highly respected researchers and
technology experts, Artelo applies leading edge scientific,
regulatory, and commercial discipline to develop high-impact
therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to Artelo’s product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies,
potential growth opportunities and other statement that are
predictive in nature. These forward-looking statements are based on
current expectations, estimates, forecasts and projections about
the industry and markets in which we operate and management’s
current beliefs and assumptions. These statements may be identified
by the use of forward-looking expressions, including, but not
limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,”
“estimate,” “potential,” “predict,” “project,” “should,” “would”
and similar expressions and the negatives of those terms. These
statements relate to future events or our financial performance and
involve known and unknown risks, uncertainties, and other factors
which may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Such factors include those set forth in Artelo’s
filings with the Securities and Exchange Commission, including our
ability to raise additional capital in the future. Prospective
investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this
press release. Artelo undertakes no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events or otherwise, except to the extent
required by applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024